The rapid and significant reduction in bone mineral density and deterioration of bone microarchitecture that specifically occurs in women following the cessation of ovarian function, primarily driven by the abrupt and profound decline in circulating estrogen levels. This accelerated phase of bone remodeling imbalance is the principal cause of postmenopausal osteoporosis, dramatically increasing the lifetime risk of fragility fractures, particularly in the spine and hip. It is a defining clinical challenge in women’s endocrinology.
Origin
This term is intrinsically linked to the physiological transition of menopause, derived from the Greek words men (month) and pausis (cessation). The clinical association between menopause and bone fragility was recognized centuries ago, but the specific hormonal mechanism was elucidated by modern endocrinology. It defines a distinct pathological process within the female lifespan.
Mechanism
The core mechanism is the loss of estrogen’s potent anti-resorptive effect. Estrogen withdrawal leads to a dramatic increase in the production of pro-osteoclastogenic cytokines, such as RANKL, which subsequently increases the differentiation, activity, and lifespan of osteoclasts, the bone-resorbing cells. While osteoblast activity attempts to compensate, the rate of bone resorption significantly outpaces formation, leading to a net negative bone balance and rapid structural decay.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.